HC Wainwright & Co. Reiterates Buy on Krystal Biotech, Maintains $221 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. has reiterated its Buy rating on Krystal Biotech, maintaining a price target of $221. Analyst Joseph Pantginis continues to show confidence in the company's prospects.
August 29, 2024 | 12:13 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. has reiterated its Buy rating on Krystal Biotech, maintaining a price target of $221. Analyst Joseph Pantginis continues to show confidence in the company's prospects.
The reiteration of a Buy rating and maintenance of a high price target by a reputable analyst can positively influence investor sentiment and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100